Ling Li, Chief Executive Officer (interim)
Ling brings to Edelweiss Immune more than 20 years experience in pharmaceutical industry business operations. Most recently, she served as Investment Director of C&Y Pharmaceutical Group, which now has more than 1500 employees and operations in China, the United States, Hong Kong and other regions. Prior to C&Y, she served as Oncology Marketing Director of Eli Lilly China, where she created marketing strategy, human resource strategy, and business and commercial plans. Her detailed understanding of the pharmaceutical industry and healthcare systems is complemented by the proven track record of fast growth market share. Earlier, Ling served as medical consultant at Pfizer. Ling holds a Degree in Pharmacy from the School of Pharmacy, Shanghai Medical University. As board director and representative of investors, Ling is responsible for operations and, management and identifying a talented executive team for Edelweiss Immune Inc.